PATHOGENIC MECHANISMS OF PRESENILIN MUTATION
早老素突变的致病机制
基本信息
- 批准号:6836479
- 负责人:
- 金额:$ 28.85万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2001
- 资助国家:美国
- 起止时间:2001-02-01 至 2006-01-31
- 项目状态:已结题
- 来源:
- 关键词:Alzheimer&aposs diseaseamyloid proteinsamyloidosisapoptosiscell differentiationcerebral degenerationdevelopmental neurobiologygene expressiongene mutationhistologyimmunocytochemistrylaboratory mousemammalian embryologymolecular pathologyneuroanatomyneurogenesisneuronsneuropathologyneurophysiologyneurotoxicologyneurotoxinspresenilinprotein localizationprotein structure functiontissue /cell culture
项目摘要
DESCRIPTION (Applicant's Abstract): Mutations in the genes encoding presenilins
1 and 2 (PS-1 and PS-2) are a leading cause of familial, early-onset
Alzheimer's disease (AD). Studies manipulating presenilin expression and
introducing mutant forms into transgenic mice and cultured cells have
demonstrated an important role for PS-1 in early brain development and
suggested potential pathogenic mechanisms for the mutations, but have technical
limitations which constrain their utility. The proposed research will extend
these efforts by evaluation of the normal and pathogenic roles of PS-1 in the
maturing and aging brain, using novel mouse models and cultured neurons derived
from them. We use gene targeting to create mouse experimental models that
emulate faithfully the genetics of familial Alzheimer's disease (mutant
"knock-in") or underexpress PS-1 into adulthood ("hypomorph"). Five mouse lines
will be studied: (1) PS-1 and APP wild type; (2) PS-1P264L knock-in; (3) APPswe
knock-in; (4) PS-1/APP double knock-in; (5) PS-1 hypomorph. Specific Aim 1 will
define functional roles of PS-1 in mouse brain maturation and aging and test
whether an FAD-linked PS-1 mutation or partial loss of PS-1 function cause
Alzheimer-type degenerative neuropathology. Comparative histological analyses
will evaluate effects of knock-in of the FAD-linked PS-1P264L mutation or PS-1
hypomorphism on neuronal death rates and the size, topology and regional
architecture of the maturing and aging mouse brain, and will address cellular
and biochemical bases for PS-1-related neuropathologies. Specific Aim 2 will
test the hypothesis that an AD-linked mutant PS-1, when expressed at normal
levels, endangers brain neurons in vitro and in vivo to degeneration. Neuronal
vulnerability to atrophy, apoptosis and necrosis will be evaluated as a
function of PS-1 genotype for cultured primary neurons of different
maturational states and for the injured adult brain. Specific Aim 3 will test
the hypothesis that an AD-linked mutant PS-1 increases production in brain of
the amyloid Abeta1-42 peptide by enhancing recruitment of a fragment of the
beta-amyloid precursor protein. The rate-limiting step in Abeta1-42 formation
will be determined by molecular and pharmacologic analyses of cultured primary
neurons, and predictions made by the "recruitment hypothesis" will be evaluated
critically in cultured neurons and the mouse brain. These studies will advance
our understanding of normal and pathogenic functions of PS-1 in the brain, and
so provide an important foundation for developing therapeutic strategies aimed
at slowing the progressive deterioration of Alzheimer's disease.
描述(申请人摘要):编码早老素的基因突变
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
ROBERT SIMAN其他文献
ROBERT SIMAN的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('ROBERT SIMAN', 18)}}的其他基金
相似国自然基金
新型F-18标记香豆素衍生物PET探针的研制及靶向Alzheimer's Disease 斑块显像研究
- 批准号:81000622
- 批准年份:2010
- 资助金额:20.0 万元
- 项目类别:青年科学基金项目
阿尔茨海默病(Alzheimer's disease,AD)动物模型构建的分子机理研究
- 批准号:31060293
- 批准年份:2010
- 资助金额:26.0 万元
- 项目类别:地区科学基金项目
跨膜转运蛋白21(TMP21)对引起阿尔茨海默病(Alzheimer'S Disease)的γ分泌酶的作用研究
- 批准号:30960334
- 批准年份:2009
- 资助金额:22.0 万元
- 项目类别:地区科学基金项目
相似海外基金
Pathophysiological mechanisms of hypoperfusion in mouse models of Alzheimer?s disease and small vessel disease
阿尔茨海默病和小血管疾病小鼠模型低灌注的病理生理机制
- 批准号:
10657993 - 财政年份:2023
- 资助金额:
$ 28.85万 - 项目类别:
Social Connectedness and Communication in Parents with Huntington''s Disease and their Offspring: Associations with Psychological and Disease Progression
患有亨廷顿病的父母及其后代的社会联系和沟通:与心理和疾病进展的关联
- 批准号:
10381163 - 财政年份:2022
- 资助金额:
$ 28.85万 - 项目类别:
The Role of Menopause-Driven DNA Damage and Epigenetic Dysregulation in Alzheimer s Disease
更年期驱动的 DNA 损伤和表观遗传失调在阿尔茨海默病中的作用
- 批准号:
10531959 - 财政年份:2022
- 资助金额:
$ 28.85万 - 项目类别:
The Role of Menopause-Driven DNA Damage and Epigenetic Dysregulation in Alzheimer s Disease
更年期驱动的 DNA 损伤和表观遗传失调在阿尔茨海默病中的作用
- 批准号:
10700991 - 财政年份:2022
- 资助金额:
$ 28.85万 - 项目类别:
Interneurons as early drivers of Huntington´s disease progression
中间神经元是亨廷顿病进展的早期驱动因素
- 批准号:
10518582 - 财政年份:2022
- 资助金额:
$ 28.85万 - 项目类别:
Interneurons as Early Drivers of Huntington´s Disease Progression
中间神经元是亨廷顿病进展的早期驱动因素
- 批准号:
10672973 - 财政年份:2022
- 资助金额:
$ 28.85万 - 项目类别:
Social Connectedness and Communication in Parents with Huntington''s Disease and their Offspring: Associations with Psychological and Disease Progression
患有亨廷顿病的父母及其后代的社会联系和沟通:与心理和疾病进展的关联
- 批准号:
10585925 - 财政年份:2022
- 资助金额:
$ 28.85万 - 项目类别:
Oligodendrocyte heterogeneity in Alzheimer' s disease
阿尔茨海默病中的少突胶质细胞异质性
- 批准号:
10180000 - 财政年份:2021
- 资助金额:
$ 28.85万 - 项目类别:
Serum proteome analysis of Alzheimer´s disease in a population-based longitudinal cohort study - the AGES Reykjavik study
基于人群的纵向队列研究中阿尔茨海默病的血清蛋白质组分析 - AGES 雷克雅未克研究
- 批准号:
10049426 - 财政年份:2021
- 资助金额:
$ 28.85万 - 项目类别:
Repurposing drugs for Alzheimer´s disease using a reverse translational approach
使用逆翻译方法重新利用治疗阿尔茨海默病的药物
- 批准号:
10295809 - 财政年份:2021
- 资助金额:
$ 28.85万 - 项目类别: